RG
ACRS icon

Redmile Group’s Aclaris Therapeutics ACRS Stock Holding History

Redmile Group’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-11,320
Closed -$68K – 82
2019
Q1 		$68K Hold
11,320
– – ﹤0.01% 81
2018
Q4 		$84K Hold
11,320
– – ﹤0.01% 75
2018
Q3 		$164K Sell
11,320
-95,500
-89% -$1.64M 0.01% 81
2018
Q2 		$2.13M Hold
106,820
– – 0.07% 65
2018
Q1 		$1.87M Sell
106,820
-200
-0.2% -$4.24K 0.07% 57
2017
Q4 		$2.64M Buy
107,020
+6,060
+6% +$148K 0.11% 60
2017
Q3 		$2.61M Buy
100,960
+6,400
+7% +$172K 0.13% 56
2017
Q2 		$2.56M Buy
94,560
+3,860
+4% +$105K 0.16% 54
2017
Q1 		$2.71M Sell
90,700
-3,500
-4% -$101K 0.18% 54
2016
Q4 		$2.56M Buy
+94,200
New +$2.4M 0.22% 44

Other funds holding ACRS

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $48.2B AUM 24.23% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2B AUM 117.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return